10 Best Promising Stocks To Buy For 2014

Today, VMware (NYSE: VMW  ) launched a new virtual operating system solution that allows customers to use their personal smartphones for work use, without compromising security or business policies.�

The new system, called VMware Horizon Mobile, is available now for�Verizon Enterprise customers on the LG Intuition and Motorola's RAZR M. The company said in a press release that more devices will be added throughout the year, but hasn't said which ones will be included.

Bill Versen, director of mobile solutions for Verizon Enterprise Solutions. "With the VMware庐 Horizon Mobile dual persona solution, Verizon enterprise customers can deliver corporate data and applications to their employees' mobile devices without impacting their personal settings and experience while ensuring that corporate information is under IT's control with a complete audit trail."

Best Net Payout Yield Stocks To Own For 2015: New Western Energy Corp (NWTR)

New Western Energy Corporation, incorporated on September 25, 2008, is an oil and gas and mineral exploration and production company with current projects located in Oklahoma, Kansas and Texas. The Company�� principal business is in the acquisition, exploration and development of, and production from oil, gas and mineral properties. The Company�� project includes Oklahoma Project, Texas Project, Kansas Project and Pennsylvania project. As of December 31, 2011, the Company�� total estimated unproved reserves were approximately 1,495,757 barrels of oil reserves. On January 2, 2012, the Company acquired of 100% interest in Royal Texan.

Oklahoma Project

This project comprises of two leases Glass and Phillips. The Glass Lease is located in Roger County, Oklahoma. The Glass leasehold property contains approximately 120 acres. The Phillips Lease is located in Rogers County, Oklahoma. The Phillips leasehold property contains approximately 150 acres. The Company�� oil leases located in Oklahoma were originally obtained from one lessor RC Oil Co.

Texas Project

This project comprises of three leases Swenson, Reves and McLellan. On January 27, 2011, the Company�� subsidiary New Western Texas acquired a 50% working interest in 160 acres of oil and gas leases in Jones County, Texas, known as the Swenson Lease. On August 8, 2011, the Company�� subsidiary New Western Texas was assigned from a third party a Paid Up Oil and Gas Lease agreement with Michael L. McLellan and Paula McLellan (Lessors), which provided us a 50% working interest in approximately 160 acres of land for the purpose of exploring for developing, producing and marketing oil and gas, along with all hydrocarbon and non-hydrocarbon substances produced.

Kansas Project

On December 20, 2011, entered into an assignment of oil and gas lease with an independent third party for an oil and gas property in Kansas referred to as Chautauqua Lease, whereby the assignor gra! nted the rights to the Company to carry on geographical and other exploratory work, including core drilling, and the drilling, and operating for producing, and marketing all of the oil, gas, including all associated hydrocarbons. As of December 31, 2011, the Company has not started any oil and gas exploration on Chautauqua Lease.

Pennsylvania project

The property is approximately 23 acres and is located on a glacial aged kame terrace. The terrace sands, gravels and finer sediments were deposited in response to blockage by glacial ice. Pennsylvania's Marcellus Shale natural gas producers operate approximately 50,000 wells and deliver more than 158 billion cubic feet of natural gas.

Advisors' Opinion:

• [By Peter Graham]
  New Western Energy Corp (OTCMKTS: NWTR) May Have Enough Cash for Now

  Small cap New Western Energy Corp is an independent energy company engaged in the acquisition, development, production, and exploration of oil, gas and minerals primarily in North America. On Friday, New Western Energy Corp fell 16% to $0.189 for a market cap of $13.02 million plus NWTR is down 37% over the past year and down 10% since February 2012 according to Google Finance.

10 Best Promising Stocks To Buy For 2014: Dreyfus Strategic Municipal Bond Fund Inc (DSM)

Dreyfus Strategic Municipal Bond Fund, Inc. (the fund) is a diversified closed-end management investment company. The fund�� investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The Dreyfus Corporation serves as the fund�� investment adviser.

The fund invests at least 80% of its assets in municipal bonds. The fund also issues auction rate preferred stock and invests the proceeds in a manner consistent with its investment objective.

Advisors' Opinion:

• [By Tom Stoukas]

  Royal DSM NV (DSM) slid 5.4 percent to 55.13 euros. The company that spent $3.2 billion on nutrition-ingredient acquisitions said profit this year may fall short of an initial target because of stagnant markets in Europe and lower chemical prices.

• [By Sherine El Madany]

  Dubai�� DFM General Index (DSM) posted the biggest drop in the Middle East, losing 2.3 percent, the most since June 10, to 2,345.47 at the 2 p.m. close in the emirate. Emaar Properties PJSC (EMAAR), developer of the world�� tallest tower in Dubai, registered its biggest decrease since April. The ADX General Index (MSM30) fell 0.9 percent, while the Bloomberg GCC200 Index (BGCC200) was down 0.2 percent.

10 Best Promising Stocks To Buy For 2014: STAAR Surgical Company(STAA)

STAAR Surgical Company, together with its subsidiaries, engages in the design, development, manufacture, and sale of implantable lenses for the cataracts and refractive surgery. It offers intraocular lenses (IOL) that include silicone Toric IOL, which is used in cataract surgery to treat preexisting astigmatism; Preloaded Injector, a three-piece silicone or acrylic IOL preloaded into a single-use disposable injector; Aspheric IOLs that provide a clearer image than traditional spherical IOLs; and nanoFLEX IOL, a single-piece collamer aspheric IOL. The company also provides implantable collamer lenses (ICL) comprising VISIAN ICL and VISIAN Toric ICL to treat refractive disorders, such as myopia, hyperopia, and astigmatism. In addition, it sells surgical products and other related instruments, as well as manufactures AquaFlow device for the treatment of glaucoma. The company markets its products to health care providers, including surgical centers, hospitals, managed care pro viders, health maintenance organizations, group purchasing organizations, and government facilities primarily under the STAAR, Visian, Collamer, nanoFLEX, nanoPOINT, CentraFLOW, AquaPORT, Epiphany, and AquaFlow names. It distributes its products through directly employed representatives, independent sales representatives, and local distributors in the United States and internationally. The company was founded in 1982 and is headquartered in Monrovia, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Sarepta Therapeutics (NASDAQ: SRPT) and STAAR Surgical Company (NASDAQ: STAA). In trading on Monday, basic materials shares were relative laggards, down on the day by about 0.45 percent.

10 Best Promising Stocks To Buy For 2014: Nissan Motor Co Ltd (NSANF.PK)

NISSAN MOTOR CO., LTD. is an automobile manufacturer. The Company has two business segments. The Automobile segment is engaged in the manufacturing, trading and distribution of various types of automobiles, marine products and accessories, as well as the research, development and sale of lithium-ion secondary batteries. The Sales Financing segment is engaged in the provision of sales financing, as well as property and casualty insurance services, among others. On November 11, 2013, the Company announced that it had established an Indonesia-based subsidiary, which is engaged in the captive finance business to make loans to the customers of Indonesia. Advisors' Opinion:

• [By Quoth the Raven]

  Regardless, through July of this year, Fusion was on pace to beat its 2012 numbers significantly.

  RankCarJuly
  2013
  YTD% ChangeJuly
  2013% Change#1Toyota (TM) Camry242,406- 0.6%34,780+ 16.3%#2Honda (HMC) Accord218,367+ 18.8%31,507+ 10.0%#3Nissan (NSANF.PK) Altima197,321+ 7.4%29,534+ 11.0%#4Honda Civic191,120+ 1.9%32,416+ 29.6%#5Toyota Corolla/Matrix183,435+ 4.6%24,463+ 3.5%#6Ford Fusion181,668+ 13.4%20,522

  - 12.0%

10 Best Promising Stocks To Buy For 2014: Lee Enterprises Incorporated (LEE)

Lee Enterprises, Incorporated provides local news, information, and advertising services primarily in midsize or small markets in the United States. The company publishes 50 daily and 39 Sunday newspapers, 300 weekly newspapers and classified, and niche publications in 22 states; and provides retail, classified, digital, and national advertising services. It also provides digital infrastructure and digital publishing services for approximately 1,500 daily and weekly newspapers and shoppers. The company was founded in 1890 and is based in Davenport, Iowa.

Advisors' Opinion:

• [By Jeff Reeves]

  Newspapers are hardly a growth industry, but after such a horrible fall from grace, publisher Lee Enterprises (LEE) may be a decent investment once more.

• [By George Putnam]

  Lee Enterprises (LEE) is a publisher of regional newspapers. Like many in its sector, the company struggled with competition from the Internet, and it went through a short bankruptcy at the end of 2011.

• [By Mike Arnold]

  I look at Glacier as one part Lee Enterprises (LEE) (community newspapers), one part Daily Journal Corp. (DJCO) (business/trade publications) with a splash of web start up. If Glacier were a drink, it would make for a delectable cocktail. Instead, its shares make for compelling investment aperitif at current prices.

10 Best Promising Stocks To Buy For 2014: Titan Pharmaceuticals Inc (TTNP.OB)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By C.R. Jackson]

  Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.

10 Best Promising Stocks To Buy For 2014: Groundstar Resources Ltd (GSA)

Groundstar Resources Limited (Groundstar) is a development-stage oil and gas company. The Company is engaged in exploration, development and production opportunities in international areas of interest. Through its subsidiaries, the Company�� primary operations are related to its interests in a production sharing contract in Kurdistan (Iraq), concession agreements in Egypt and a petroleum prospecting license in Guyana. Advisors' Opinion:

• [By Damian Illia]

  The company�� revenues come from the fees charged for operating different domain names. Most domain names��fees are charged as per agreement terms with ICANN; however, fees received for operating the .gov registry are based on the terms of agreement with the U.S. General Services Administration (GSA). As of September 2013, revenues of $125.9 million came from active domain names ending with .com and .net. Even though the company has presence all over the globe, the U.S. contributes 64.8% of revenues, while Europe, the Middle East and Africa (EMEA) contribute 15.5%, Australia, China, India and other Asia Pacific countries (APAC), 15.0%, and other countries such as Canada or Latin American countries, contribute 4.7%. Competition is increasing, especially with Latin script ccTLD registries and IDN ccTLD registries, as well as with other name service providers such as Neustar Inc. (NSR) or ARI Registry Services, and search engine providers such as Google Inc. (GOOG) Microsoft, Corp. (MSFT).